Introduction
============

Over recent years there has been a surge of interest in vision restoring therapies that replace the function of dead or dying photoreceptors using a variety of genetic, electronic or transplantation methods ([@B5]; [@B34]). For any of these treatments to succeed, a basic requirement is that the circuitry of the inner retina remains functionally intact and capable of passing visual information to higher visual centers. Yet, over recent years, the notion that the inner retina remains intact following complete loss of photoreceptors has been questioned ([@B22]; [@B26], [@B25]; [@B43]; [@B21]; [@B8]). A range of changes occur in both neurons and glial cells in animal models of inherited retinal degeneration, as well as humans with retinitis pigmentosa (RP). These changes are classified into three phases based on retinal anatomy ([@B21]); Phases 1 and 2 refer to the periods of rod photoreceptor and cone photoreceptor death, respectively, while phase 3 is characterized by major anatomical changes in the inner retina including re-wiring of neural processes and the formation of a glial seal that encases the remaining retina ([@B26]). As most vision restorative therapies will be employed after photoreceptor death, a greater understanding of the events that occur in phase 3 degeneration will assist in optimizing these therapeutic approaches.

The rd1 mouse is the most widely studied mouse model of retinal degeneration ([@B11]; [@B13]). It carries a gene mutation in the β subunit of phosphodiesterase 6 (*Pde6b*), which is a similar genetic defect to patients with autosomal recessive RP ([@B35]; [@B30]). Studies have documented both functional and anatomical changes in this mouse model of degeneration ([@B42]; [@B44]; [@B22]; [@B27]). Apart from the obvious structural changes in the outer retina (the loss of photoreceptors), there are also functional changes in bipolar and ganglion cells within this early period of degeneration ([@B40]; [@B8]; [@B41]; [@B16]). However, at later stages of degeneration after photoreceptor loss, neurons of the inner retina also show significant anatomical alterations, including migration of somata to ectopic sites, the establishment of aberrant synapses, neuronal death, and glial remodeling ([@B22]; [@B26]; [@B9]). Finally, while neurochemical changes have been described both at early and late stages of degeneration in the rd1 mouse, as well as in other models of retinal degeneration ([@B14], [@B15]; [@B26]; [@B21]; [@B16]), the underlying cause and relationship between the different forms of inner retinal change is not clear. For that reason a model system probing these inner retinal changes would be of use.

The Fos-Tau-LacZ (FTL) mouse has an axonally targeted reporter system under the regulation of the *c-fos* promoter ([@B47]). *C-fos* is an intermediate early gene that is known to be up-regulated in neurons in response to neural activity, cell death, and/or plasticity ([@B28]; [@B37]; [@B47]; [@B18], [@B17]). FTL mice have been useful for visualizing neural circuits activated by a range of stimuli, including those involved in regulating water balance ([@B47]), learning and memory ([@B1], [@B2]) and respiratory control within the nuclei of the brainstem ([@B33]). When FTL mice are bred with rd1 mice, photoreceptors display increased *c-fos* reporter labeling from an early age that follows closely the time course of photoreceptor death ([@B17]). However, nothing is known about *c-fos* reporter (FTL) regulation at later stages of degeneration in the rd1-FTL mouse and whether this relates to inner retinal neural change.

In view of the increase in aberrant neural activity, plasticity changes and possible cell death that takes place within the inner retina at late stages of degeneration, the rd1-FTL mouse could provide a useful tool for studying the cellular changes that occur in the inner retina well after photoreceptor cell death. In this study we examined the time course of *c-fos* reporter expression in the rd1-FTL mouse and characterized the accompanying glial and neuronal alterations. Our results show that *c-fos* reporter (FTL) expression is upregulated in inner retinal neurons within discrete patches in the central retina from 4 months of age. Moreover, increased FTL expression coincides with regions displaying considerable Müller cell change and loss of cone photoreceptor terminals. These areas may represent regions of the retina from which the glial seal may form. Targeting restorative therapies distant to these retinal areas may improve outcomes.

Materials and Methods {#s1}
=====================

Animals
-------

All animal procedures were performed in accordance with the University of Melbourne Animal Experimentation Ethics Committee and with guidelines outlined by the National Health and Medical Research Council and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research.

Rd1-FTL double-mutant mice were created by breeding rd1 homozygous mice with heterozygous FTL transgenic animals ([@B47]). Rd1 mice were originally obtained from Professor Debora Farber, University of California, Los Angeles, CA, USA and backcrossed more than 10 times with the C57Bl6J^ARC^ obtained from the Animal Resource Centre (Western Australia). FTL mice were originally generated at the University of Melbourne (Parkville, Australia; [@B47]). The rd1-FTL mouse expresses a mutation in the β subunit of *Pde6b* gene, resulting in retinal degeneration, together with an axonally targeted transgenic marker gene (β-galactosidase) that labels all neurons that have *c-fos* promoter activation ([@B17]). Mice examined in this study were aged from 2 to 12 months and control heterozygous FTL mice were age matched for comparison (at least *n* \> 7 rd1-FTL and FTL at each age group per outcome measure). All mice used in this study were confirmed to be free of the rd8 mutation in the *Crb1* gene ([@B29]).

Tissue Collection and Fixation
------------------------------

Mice were killed by an overdose of sodium pentobarbital (Merial Australia, Parramatta, Australia: 120 mg/kg, intraperitoneal). Eyes were then immediately dissected, the anterior segment and lens discarded and the posterior eyecup fixed in one of two ways depending on the type of immunofluorescence to be performed. Posterior eye cups that were processed for indirect immunofluorescence were fixed in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer, pH 7.4 (phosphate buffered, PB) for 30 min, washed in PB and subsequently processed through graded sucrose solutions (10, 20, and 30% w/v sucrose in PB). Samples were stored at --80°C until use.

A subset of eyes from rd1-FTL and FTL mice (*n* \> 8 eyes) were processed for β-galactosidase histochemistry, whereby the mouse was transcardially perfused with 12 ml of 5% sucrose in dH~2~O, followed by 12 ml of PFA with 0.005% glutaraldehyde in PB. Eyes were immediately dissected and a hole pierced in the eyecup at the corneal margin with a 30G needle. Eyes were then placed in 4% PFA and the anterior eyecup and lens were removed. The posterior eyecup was postfixed in 4% PFA for 10 min and then placed in phosphate buffered saline (PBS). All eyes were immediately processed for enzyme histochemistry.

β-Galactosidase Histochemistry on Wholemount Retinae
----------------------------------------------------

Retinae were dissected from the posterior eyecup and placed in the staining buffer (5 mM magnesium chloride, 5 mM potassium ferrocyanide, 5 mM potassium ferricyanide, and 0.4 mg/ml 5-Bromo-4-chloro-3-indolyl-B-[D]{.smallcaps}-galatocpyranoside) for 16 h under rotation at room temperature ([@B18], [@B17]). To stop the reaction, an equivalent volume of 4% PFA was added to the solution and the retina was washed in PBS and mounted onto 0.5% gelatine/5% chromium potassium sulfate-coated slides. Wholemounts were air-dried on slides and dehydrated through graded alcohols to histolene and mounted in Safety Mount (Fronine, Riverstone, Australia). Wholemount retinae processed for β-galactosidase histochemistry were viewed using a light microscope with either a 4 × air objective or 40 × oil objective and tissue was imaged using an ImagePoint cooled CCD camera (Photometrics LTD, Tucson, AZ, USA) and assessed using Windows imaging software (Digital Optics Ltd., Auckland, NZ). The extent of β-galactosidase expression (FTL labeling) was quantified as a percentage of total retinal area from *n* ≥ 8 retinae (mm^2^ FTL labeling/mm^2^ retinal area).

Immunofluorescence
------------------

Changes in cells in FTL and rd1-FTL mice were evaluated on vertical sections of retina using indirect immunofluorescence as previously described ([@B12]; [@B10]; [@B45]). Briefly, sections (14 μm in thickness) were cut from OCT (Tissue Tek, Sakura Finetek, Tokyo, Japan) embedded eyecup blocks and mounted onto 0.5% gelatine/5% chromium potassium sulfate coated slides that were then air-dried. Slides were washed in PB and primary antibody was applied overnight. Following incubation, sections were again washed in PB and secondary antibody was applied for 40 min. **Table [1](#T1){ref-type="table"}** contains a list of the primary and secondary antibodies that were used. All antibodies were diluted in buffer consisting of 3% normal goat serum, 1% bovine serum albumin and 0.5% Triton X-100 in PB. Cell death was measured using a commercially available fluorometric terminal dUTP nick-end labeling (TUNEL) kit (DeadEnd Fluoro metric TUNEL system, Promega, Madison, WI, USA). Slides were then washed in PB, and mounted and cover-slipped with fluorescent mounting medium (DAKO, Carpinteria, CA, USA).

###### 

List of the primary and secondary antisera used in this study.

  Antiserum                           Dilution/Species                  Source/Cat. No.
  ----------------------------------- --------------------------------- -----------------------------------------------------------------------------------
  β-galactosidase                     1:10,000 Rabbit polyclonal        MP Biomedicals; Cat\#08559761
  β-galactosidase                     1:10,000 Chicken polyclonal       Abcam; Cat\#AB9361
  Calretinin                          1:500 Mouse monoclonal            Swant; clone 6B3
  CyclinD1                            1:1 Rabbit polyclonal             Merck Millipore; Cat\#04-1151
  GABA                                1:500 Guinea pig polyclonal       Merck Millipore; Cat\#AB175
  Glutamate                           1:45,000 Rabbit polyclonal        Gift from Dr Robert E Marc, available through Chemicon International; Cat \#AB133
  Glial fibrillary acid protein       1:20,000 Rabbit polyclonal        DAKO; Cat\# Z0334
  Glycine                             1:50,00 Rabbit polyclonal         Gift from Prof David Pow, University of Queensland, Brisbane, QLD, Australia
  GLAST (EAAT1)                       1:1,000 Rabbit polyclonal         Abcam; Cat\# AB41751
  Vesicular glutamate transporter 1   1:20,000 Guinea pig, polyclonal   Merck Millipore; Cat \#AB5905
  Glutamine synthetase                1:1,000 Mouse monoclonal          Merck Millipore; Cat\# MAB302
  Tyrosine hydroxylase                1:1,000 Mouse monoclonal          Chemicon International; Cat \#MAB318
  Kir4.1                              1:1,000 Rabbit polyclonal         Merck Millipore; Cat\#AB5818
  Neuron specific nuclear protein     1:500 Mouse monoclonal            Merck Millipore; Cat\# MAB377
  Peanut Agglutinin-Rhodamine         1:250 Fluorescent Lectin          Vector Labs; Cat \#RL-1072
  Sox9                                1:500 Rabbit polyclonal           Merck Millipore; Cat\# AB5535
  Anti-Rabbit Alexa594                1:800 Goat polyclonal             Life Technologies; Alexa Fluor^®^ Cat\# A11037
  Anti-Mouse Alexa488                 1:500 Goat polyclonal             Life Technologies; Alexa Fluor^®^\_Cat\# A11001
  Anti-Guinea pig Alexa594            1:500 Goat polyclonal             Life Technologies; Alexa Fluor^®^\_Cat\# A11076
  Anti-Guinea pig Alexa488            1:500 Goat polyclonal             Life Technologies; Alexa Fluor^®^ Cat\# A11073
  Anti-Chicken Alexa594               1:500 Goat polyclonal             Life Technologies; Alexa Fluor^®^ Cat\# A11042
  Anti-Mouse Alexa647                 1:500 Goat polyclonal             Life Technologies; Alexa Fluor^®^ Cat\# A21235
  BisBenzimide H                      0.1 mg/mL                         Sigma Aldrich; Cat\#14530

Retinal sections processed for immunofluorescence and TUNEL were viewed on a confocal laser scanning microscope (LSM 510 PASCAL, Zeiss, Oberkochen, Germany) using either a 20 × air objective or a 40 × oil objective and images were captured at a resolution of 512 × 512 or 1024 × 1024 pixels using Zeiss LSM image browser software and an appropriate fluorescence filter (Alexa TM 594/CY3: excitation 568 nm, emission filter 605/32; Alexa TM 488/FITC: excitation 488 nm, emission filter 522/32; Alexa TM 647/CY5: excitation 647 nm, emission filter 680/32). Images were collated using Adobe Photoshop CS5 (Adobe Systems, San Jose, CA, USA).

Histological Analysis
---------------------

The immunolabeling of each antibody was assessed across at least *n* ≥ 6 eyes, with three separate sections imaged per eye. The co-localisation of FTL labeling with specific cell markers was quantified and expressed as a percentage of the total number of FTL positive cells \[%, (co-label of FTL and cell marker/total cells stained for FTL) × 100\]. The markers of retinal Müller cells were quantified in control (FTL) and rd1-FTL retinae (areas exhibiting FTL labeling and neighboring areas lacking expression of FTL) as cell number per mm of retina (*n* ≥ 6). Total and inner retinal thickness measures were calculated from central retinal sections (*n* = 6 eyes, at least three sections per eye) that showed FTL labeling and neighboring regions that lacked FTL expression (assessed after indirect immunofluorescence, processed with ImageJ 1.43 freeware, NIH).

Statistical Analysis
--------------------

A one-way analysis of variance (ANOVA) with a Tukey's multiple comparison *post hoc* test was used to statistically compare the change in *c-fos* reporter labeling across the rd1 retina. The quantification of glutamine synthetase (GS), Sox9, and cyclin D1 immunolabeling was analyzed using a two-way ANOVA, with Tukey's multiple comparison *post hoc* test to evaluate the differences. GraphPad Prism (San Diego, CA, USA) was used to graph data and to perform the above statistical analyses.

Results
=======

This study examined the retinal changes that take place at late stages of degeneration (6--7 month-old animals) in the rd1-FTL mouse model of retinal degeneration. The rd1-FTL mouse has an axonally targeted reporter system under the control of the *c-fos* promoter ([@B47]), as well as carrying a homozygous mutation in *Pde6b*. In the results described below, an increase in the *c-fos* reporter is referred to as "FTL" labeling.

FTL Labeling is Increased in Inner Retinal Neurons Well after Photoreceptor Degeneration
----------------------------------------------------------------------------------------

Using β-galactosidase histochemistry, the time course of FTL labeling was assessed in rd1-FTL mice up until 1 year of age and compared to age-matched control FTL mice. In the adult (post-natal day 135, P135) control retina (**Figure [1A](#F1){ref-type="fig"}**), FTL labeling covered the entire retina and as described previously, was found in a range of inner retinal neurons ([@B18]). By contrast, FTL labeling was virtually absent in the rd1-FTL retina at a similar age (P105, **Figure [1B](#F1){ref-type="fig"}**). By P135 (**Figure [1C](#F1){ref-type="fig"}**), there were discrete regions of FTL labeling lateral to the optic disk in the rd1-FTL retinae. Over time, this labeling spread to cover the central retina (**Figure [1D](#F1){ref-type="fig"}**), although the peripheral retina never showed labeling, even after 12 months (data not shown).

![**Fos-Tau-LacZ (FTL) reporter expression increases in the rd1-FTL retina as a function of age.** Flatmount retinae from control FTL (**A**, P135), rd1-FTL (**B**, P105; **C**, P135; **D**, P240; **E**, dark adapted rd1-FTL aged P210) mice were processed for FTL expression using β-galactosidase histochemistry. In contrast to the wild-type retina that showed FTL labeling throughout the retina **(A)**, the rd1-FTL aged P105 **(B)** showed no FTL labeling. However, at P135 **(C)** rd1-FTL retina showed distinct labeling near the optic nerve, that subsequently expanded across the central retina **(D**,**E)**. The expression of the FTL reporter as a function of retinal area was quantified at different ages from P105 to P365 **(F)**. Data presented as mean ± SEM, *n* ≥ 8 per group, ^∗∗∗∗^*p* \< 0.0001 (one-way ANOVA). Scale bar for **(A**--**E)** = 1 mm.](fncel-09-00293-g001){#F1}

Previous studies in young rd1-FTL animals (≤P30) have shown that FTL labeling in the retina is influenced by light activation ([@B18]). In order to determine whether this increase in FTL labeling observed at this late stage of degeneration (≥P135) was also dependent on light activation, 7 month-old rd1-FTL animals were dark-adapted prior to enucleation and β-galactosidase histochemistry. No difference in the labeling pattern between the light (**Figure [1D](#F1){ref-type="fig"}**) and dark-adapted (**Figure [1E](#F1){ref-type="fig"}**) rd1-FTL retinae was observed, indicating this increase in FTL labeling is independent of light-induced activation. Quantifying the extent of FTL labeling in the retina showed an age-dependent increase in expression after 105 days post-natal, with 29 ± 3% of the total retinal area exhibiting FTL labeling out to 1 year of age (**Figure [1F](#F1){ref-type="fig"}**, one-way ANOVA, *p* \< 0.0001, *n* ≥ 8 per group).

The retinal cell types that were responsible for this increase in FTL expression were evaluated using immunofluorescence in 6 month-old rd1-FTL retinae. As shown in **Figures [2A,C](#F2){ref-type="fig"}** and **[E](#F2){ref-type="fig"}**, cells in the inner retina were positive for FTL labeling (anti-β-Gal, red). In order to determine the types of cells expressing FTL immunoreactivity, double labeling experiments were performed with markers of amacrine cells including, GABA, glycine, and tyrosine hydroxylase. FTL was observed to co-localize with GABA (**Figure [2B](#F2){ref-type="fig"}**, arrows) and glycine (**Figure [2D](#F2){ref-type="fig"}**, arrows), but not tyrosine hydroxylase (**Figure [2F](#F2){ref-type="fig"}**), suggesting that in late stage degeneration, GABAergic and glycinergic amacrine cells express the *c-fos* reporter, while dopaminergic amacrine cells do not. This is unlike the inner retinal labeling observed in this model during the early stages of photoreceptor degeneration (\<P26) where dopaminergic amacrine cells also express the *c-fos* reporter ([@B17]).

![**Amacrine and ganglion cells express the FTL reporter within the inner retina of rd1-FTL.** Retinal sections of rd1-FTL mouse (6 months of age) were labeled with anti-β-galactosidase (**A**,**C**,**E**; red), which identifies FTL reporter expression (see white arrows in **A**,**C**). Retinal sections were co-labeled with GABA **(B)**, or glycine **(D)** showing FTL was co-localized within subpopulations of GABA immunoreactive (**B**, white arrows) and glycine immunoreactive (**D**, white arrows) amacrine cells. Retinal wholemounts were double labeled with anti-β-galactosidase and tyrosine hydroxylase (**E**,**F**; respectively) and no co-localization was evident. Rd1-FTL wholemount from a 4.5 month-old animal was also labeled using β-galactosidase histochemistry showing ganglion cell axons projecting to the optic nerve express the reporter (**G**, black arrows). This ganglion cell expression was confirmed in vertical sections of rd1-FTL retina, which were triple labeled for β-galactosidase (red), GABA (green) and NeuN (Blue). There are numerous cells in the GCL that are co-labeled with FTL and NeuN (**H**, white arrows). Abbreviations: INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer, OD, optic disk. Scale bar for **(A**--**F**,**H)**: 50 μm; **(G)**: 250 μm.](fncel-09-00293-g002){#F2}

β-galactosidase histochemical labeling of the rd1-FTL retina showed evidence of reporter expression within ganglion cell axons (**Figure [2G](#F2){ref-type="fig"}**, black arrows). In order to assess ganglion cell expression of the *c-fos* reporter, NeuN was used to label all neurons in the ganglion cell layer (GCL), while GABA immunolabeling was used to exclude displaced amacrine cells. Triple labeling with antibodies to β-Gal, NeuN, and GABA identified numerous ganglion cells that were labeled for FTL (NeuN positive, GABA negative, **Figure [2H](#F2){ref-type="fig"}**, see arrows). Quantification of FTL positive cells in the inner retina revealed that 28 ± 8% of FTL immunoreactive cells were strongly GABA immunoreactive, 41 ± 20% were strongly glycine immunoreactive, while within the GCL, 16 ± 5% were NeuN^+^/GABA^-^ neurons (*n* ≥ 6 animals). These data suggest that specific subpopulations of conventional amacrine cells and ganglion cells express the *c-fos* reporter during the later stages of retinal degeneration.

FTL expression during Late-Stage Degeneration Does Not Reflect Inner Retinal Thinning, Nor Exclusively Correlate with Remodeling
--------------------------------------------------------------------------------------------------------------------------------

*c-fos* is known to be upregulated during cell death ([@B28]). Indeed, our previous study of rd1-FTL mice showed FTL labeling in photoreceptor nuclei during the period of rod loss between post-natal day 10 and 30 ([@B17]). In order to determine whether the amacrine and ganglion cell labeling observed at late stages of retinal degeneration was associated with cell death, inner nuclear layer (INL) thickness was quantified in FTL immunolabeled regions and non-labeled areas that were immediately adjacent. The INLs of the FTL positive regions were not significantly different to the adjacent negative regions (**Figure [3A](#F3){ref-type="fig"}**, FTL^+^ 30 ± 2, FTL^-^ 31 ± 3 μm, *p* \> 0.05, *n* ≥ 6 animals), while total retinal thickness was also unchanged (**Figure [3A](#F3){ref-type="fig"}**, FTL^+^ 84 ± 8, FTL^-^ 84 ± 8 μm, *p* \> 0.05, *n* ≥ 6 animals). To confirm the lack of cell death involvement in FTL labelling, TUNEL labeling was performed within the inner retina of 4 and 6 month-old rd1-FTL mice. Limited staining was detected, similar to that observed in age-matched FTL controls (data not shown). These findings suggest that at this late stage of retinal degeneration, the FTL labeling observed in the amacrine and ganglion cells of the rd1-FTL retina is unlikely to be the result of cell death.

![**Fos-Tau-LacZ reporter expression in the rd1-FTL retina is not due to cell death nor correlated with remodeled inner retina.** Total and inner nuclear layer thickness measures were measured from vertical retinal sections in areas exhibiting FTL expression, as well as neighboring areas showing no FTL expression **(A)**. Additionally, vertical sections of rd1-FTL retina were labeled for FTL (anti-β-galactosidase, green) and DAPI (blue). Inner retinal layer and total retinal thickness' were similar between FTL^+^ sand FTL^-^ regions **(A)**. Increased FTL reporter expression was observed in inner retinal regions where the structure remained intact **(B)**, as well as in regions where there was evidence of anatomical remodeling (arrows, **C**). Furthermore, other regions that exhibited DAPI labeled nuclei which were mislocated within the IPL, were FTL negative (arrows, **D**). Data presented as mean ± SEM, *n* ≥ 6 per group, *p* \> 0.05 (two-way ANOVA). Abbreviations: INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar: 50 μm.](fncel-09-00293-g003){#F3}

As *c-fos* expression has been associated with neural plasticity, retinal areas exhibiting anatomical remodeling were correlated to FTL labeling. As shown in **Figure [3B](#F3){ref-type="fig"}**, FTL labeling occurred in areas with normal inner retinal morphology, as well as in regions with abnormally localized nuclei in the IPL, indicative of anatomical remodeling (arrows in **Figure [3C](#F3){ref-type="fig"}**). However, other regions that exhibited mislocalised DAPI-labeled nuclei within the IPL, were FTL negative (arrows in **Figure [3D](#F3){ref-type="fig"}**). Thus, FTL labeling in the inner retina did not exclusively coincide with areas that showed evidence of remodeling, suggesting that FTL up-regulation does not solely reflect neuronal plasticity changes in the rd1-FTL retina.

FTL Labeling of Inner Retinal Neurons is Localized to Regions of Aberrant Glia
------------------------------------------------------------------------------

The labeling within the rd1-FTL retina was patchy, with some regions showing FTL in cell somata of the INL (**Figure [4A](#F4){ref-type="fig"}** arrow, **Figure [4D](#F4){ref-type="fig"}** highlighted region), whereas neighboring areas showed no cell soma labeling. There was, however, a relatively consistent labeling within the GCL likely due to *c-fos* reporter expression within axons (**Figure [4D](#F4){ref-type="fig"}**, also see **Figure [2G](#F2){ref-type="fig"}**). Müller cell labeling with GS (green; [@B3]) also showed a variability in staining (**Figure [4B](#F4){ref-type="fig"}** arrow, **Figure [4E](#F4){ref-type="fig"}** highlighted region) and revealed an intriguing inverse correlation, with FTL expression observed in retinal regions that were either devoid of, or showed a major reduction in, GS labeling (**Figures [4C,F](#F4){ref-type="fig"}**).

![**Fos-Tau-LacZ positive regions within the rd1-FTL retina show Müller cell alterations.** Vertical sections of the rd1-FTL mouse retina (6 month-old) were labeled for FTL (**A**,**D**; anti-β-galactosidase, red) and glutamine synthetase (GS; **B**,**E**; green) and areas of co-localisation assessed **(C**,**F)**. Regions that are intensely labeled for FTL correspond to regions that show low GS labeling (white arrow; **B, C**). High magnification of the FTL expressing region within the rd1-FTL retina is indicated by the white bracket and corresponds to an area of low GS labeling. Abbreviations: INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar: 250 μm **(A**--**C)**, 50 μm **(D**--**F)**.](fncel-09-00293-g004){#F4}

Müller cells are integral to maintenance of retinal structure and function, being involved in potassium siphoning, glutamate and GABA turnover, chromophore recycling, energy metabolism and maintenance of the blood retinal barrier ([@B4]). To examine whether these Müller cell metabolic processes might be compromised, rd1-FTL retinae were labeled for Kir4.1 the predominant glial inwardly rectifying potassium channel ([@B23]), GLAST, the principal glutamate transporter expressed by Müller cells ([@B24]; [@B36]), and glial fibrillary acidic protein (GFAP), a marker of Müller cell gliosis. As shown in **Figure [5](#F5){ref-type="fig"}**, regions of the rd1-FTL retina that showed reduced GS immunolabeling also showed reduced Kir4.1 staining (**Figures [5A--C](#F5){ref-type="fig"}**). However, while GLAST-labeling was still detected within these regions (**Figures [5D--F](#F5){ref-type="fig"}**), it appeared abnormal when compared to neighboring GS-expressing regions. These altered regions showed extensive GFAP labeling (**Figures [5G--I](#F5){ref-type="fig"}**), which has been reported previously in the rd1 mouse retina ([@B40]; [@B8]; [@B41]; [@B16]). These data suggest that while GS and Kir4.1 expression is significantly reduced, gliotic Müller cells with the potential for glutamate uptake remained within these aberrant regions.

![**Müller cells are altered in the FTL positive regions within the rd1-FTL retina.** Vertical sections of rd1-FTL retinae (7 month-old) were labeled for glutamine synthetise **(A,D,G)**, Kir4.1 **(B)**, GLAST **(E)**, or GFAP **(H)**, with the double label shown in **(C,F,I)**. Areas that showed little GS labeling (in between arrow heads in **C** and **F**) corresponded to Müller cells that lacked Kir4.1. Despite this, these areas still showed GLAST immunolabelling. These altered regions were also positive for the gliosis marker GFAP. Abbreviations: INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar: 50 μm.](fncel-09-00293-g005){#F5}

These results imply that after photoreceptor degeneration in the rd1-FTL retina, localized subpopulations of amacrine and ganglion cells show increased FTL expression in regions where Müller cells are dysfunctional or absent. In order to determine if Müller cell loss occurred in these FTL-expressing regions, retinal sections were co-labeled for GS and Sox9, a Müller cell nuclear marker. As shown in **Figure [6](#F6){ref-type="fig"}**, Sox 9 labeling was 100% co-localized with GS positive Müller cells in control retinae (**Figure [6A](#F6){ref-type="fig"}**), and in areas of the rd1-FTL retina that were GS positive (**Figure [6B](#F6){ref-type="fig"}**). By contrast, FTL positive areas that almost completely lacked GS, still showed some cells that were Sox9 immunoreactive (**Figure [6B](#F6){ref-type="fig"}**, highlighted region). Quantifying the number of GS and Sox9 immunoreactive Müller cells in control FTL and rd1-FTL (FTL^+^ or FTL^-^ regions) retinae (**Figure [6E](#F6){ref-type="fig"}**), showed a significant reduction in immunoreactive somata between FTL positive areas and control retinae (GS, --87 ± 2%; Sox9 --56 ± 7%; two-way ANOVA, *p* \< 0.0001, *n* ≥ 6) as well as FTL positive and negative regions (GS, --86 ± 2%; Sox9 --53 ± 7%; two-way ANOVA, *p* \< 0.0001, *n* ≥ 6). There were no significant differences between control retinae and FTL negative regions of the rd1-FTL retinae (GS, --7 ± 6%; Sox9, --6 ± 5%: two-way ANOVA, *p* \> 0.05, *n* ≥ 6).

![**Müller cells in the FTL positive regions within the rd1-FTL retina show evidence of proliferative gliosis.** Vertical sections of 6 month-old control FTL **(A)** and rd1-FTL **(B)** retina were double-labeled for GS (green) and SOX9 (red). Sox 9 immunolabeled Müller cell somata were present in regions that showed little or no labeling for GS. Control FTL **(C)** and rd1-FTL **(D)** were double labeled for GS (green) and Cyclin D1 (red). Cyclin D1 expression was only found in regions that showed little or no GS. GS, Sox9, and ClyclinD1 expression was quantified in control FTL retinae, and in rd1-FTL retinae in areas with and without FTL reporter expression **(E)**. Data are expressed as mean immunoreactive cells per mm retina ±SEM *n* ≥ 6 per group, ^∗^*p* \< 0.0001 (two-way ANOVA). Abbreviations: INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar: 50 μm.](fncel-09-00293-g006){#F6}

As these FTL-positive areas exhibited several markers of proliferative gliosis (reduced GS, and Kir4.1 expression and increased GFAP), cyclinD1 was used to determine whether Müller cells in these affected regions had altered cell cycle regulation. Increased cyclinD1 expression in Müller cells has been previously reported during late stage retinal degeneration ([@B46]). As shown in **Figure [6C](#F6){ref-type="fig"}**, no cells in the age-matched control retinae showed cyclinD1 expression. However, within FTL^+^/GS^-^ regions of the rd1-FTL retina, numerous Müller cells showed cyclinD1 expression (**Figure [6D](#F6){ref-type="fig"}**, highlighted region). When quantified (**Figure [6E](#F6){ref-type="fig"}**), a significantly higher number of cyclinD1 immunoreactive Müller cells were found in regions of FTL labeling compared to control (FTL^+^ regions 53 ± 5 cells/mm retina; control FTL 0.6 ± 0.4 cells/mm retina; two-way ANOVA, *p* \< 0.0001, *n* ≥ 6), or neighboring FTL negative regions (FTL^+^ regions 53 ± 5 cells/mm retina; FTL^-^ regions 4 ± 2 cells/mm retina; two-way ANOVA, *p* \< 0.0001, *n* ≥ 6). These results highlight that well after photoreceptor degeneration, inner retinal FTL expression coincides with distinct regions that show reduced Müller cell number (reduced Sox9), with the remaining cells exhibiting aberrant expression of functional markers, including Kir4.1, GS, and cyclin D1.

Cone Loss Occurs in Regions of Glial Loss and Abnormality
---------------------------------------------------------

At late stages of retinal degeneration, phase 3 remodeling is characterized by marked anatomical changes that are thought to be precipitated by the loss of cone photoreceptor terminals. The association of cone-mediated remodeling on the patches of glial abnormality and FTL expression was assessed in the rd1-FTL (*n* ≥ 6 animals). **Figure [7](#F7){ref-type="fig"}** shows representative vertical sections taken from 6 month-old animals that were double labeled with GS and vesicular glutamate transporter (VGLUT1) a marker for the glutamate transporter within glutamatergic terminals ([@B39]). Regions that showed GS labeling (**Figure [7A](#F7){ref-type="fig"}**) also displayed VGLUT1 labeling (**Figure [7B](#F7){ref-type="fig"}**), whereas areas that had low levels of GS immunolabelling, corresponded to regions that showed a complete loss of photoreceptor terminals as indicated by an absence of VGLUT1 labeling (**Figure [7C](#F7){ref-type="fig"}**). This finding was confirmed with labeling for the cone marker, peanut agglutinin, with normal GS regions exhibiting remnants of cone terminals, whereas GS depleted regions showed no labeling of synaptic terminals (data not shown). Overall, the results of this study highlight that during late stage retinal degeneration there are localized changes in inner retinal neurons (amacrine and ganglion cells) that are coincident with aberrant Müller cells and that these regions correspond to regions where cone terminals are lost.

![**Cone photoreceptor loss is evident in areas containing aberrant Müller cells.** Vertical sections of 6 month-old rd1-FTL retinae were double labeled for VGLUT1 (red) and GS (green) in order to investigate the presence of cone photoreceptor terminals in FTL-rich regions. VGLUT1 immunolabeling is expressed in the OPL and IPL **(A)**. High magnification of the OPL shows that in regions where GS is expressed, cone photoreceptor terminals remain **(B)**, however, in areas of low to no GS **(C)**, VGLUT expression is absent. Abbreviations: OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Scale bar: 50 μm.](fncel-09-00293-g007){#F7}

Discussion
==========

*c-fos* is an intermediate early gene that is known to be regulated during cell death, altered neural function and neural plasticity. From approximately 4 months of age, a time where most photoreceptor nuclei have been lost, *c-fos* reporter (FTL) expression was increased in subsets of amacrine and ganglion cells across the central rd1-FTL retina. These regions of FTL expression were not correlated with cell death or inner retinal remodeling. These areas did correspond to discrete regions of abnormal Müller cells which showed reduced GS, Kir4.1, and Sox9 immunolabelling, in addition to aberrant cell cycle regulation. Furthermore, these aberrant Müller cells were present in regions that showed a complete loss of cone photoreceptor terminals. These results highlight that inner retinal changes occur in the rd1-FTL retina in a localized fashion and are associated with the loss of cone photoreceptor terminals and Müller cell anomalies.

FTL Expression as a Marker of Inner Retinal Change
--------------------------------------------------

The results of this study show that *c-fos* reporter (FTL) expression changes in the rd1-FTL with age. Consistent with our previous findings ([@B17]), retinal FTL expression was low at 3 months of age in the rd1-FTL compared to control FTL mice, most likely reflecting the lack of neural activity at this age. This is supported by previous work that indicates virtually all photoreceptor nuclei are lost in the central rd1 retina by 2 months of age ([@B19]). While FTL expression was initially low, it re-emerged within subpopulations of both amacrine and ganglion cells by 4 months of age (from P120). This increase in expression was not due to light-induced neuronal activation as we have previously reported in young (\>P30) rd1-FTL animals ([@B18]). Over the next 8 months (P120--P365) FTL expression increased within the central retina, yet never extended out into the peripheral retina. It must be highlighted that the oldest animals used in this study were 1 year of age and so peripheral FTL expression after this time cannot be discounted. The reason for this central localisation of *c-fos* reporter expression is unclear, however, a central to peripheral gradient in retinal degeneration has been reported in both the rd1 and rd1-FTL retinae ([@B6]; [@B17]).

The FTL transgene was used as a reporter for *c-fos*, an early intermediate gene that is known to be upregulated during cell death, neural function and neural plasticity. The increase in FTL expression in the amacrine and ganglion cells from 4 months of age was not associated with an increase in inner retinal cell death, as our results showed no difference in thickness of the INL, in either FTL-immunolabeled regions or neighboring FTL-negative regions. There was also no appreciable level of TUNEL labeling and certainly no specific localisation to FTL^+^ regions. Furthermore, the data did not support a role for *c-fos* reporter expression as a biomarker of inner retinal remodeling since anatomical remodeling was observed in FTL^+^ regions, as well as FTL^-^ regions. With previous work on the rd1 mouse model showing evidence of altered inner retinal neurochemistry, as well as aberrant amacrine and ganglion cell function ([@B40]; [@B8]; [@B7]), it is possible that these functional alterations are related to the observed FTL expression.

Our data showed that anomalies in glial cells, specifically Müller cells, coincide with the localized regions of FTL up-regulation. Based on the Sox9 labeling, Müller cells were reduced in number within FTL^+^ regions of retina. In addition, the Müller cells that remained in these regions were gliotic and showed reduced glutamate synthetase and Kir4.1 immunolabelling. In view of the importance of both glutamate turnover and potassium siphoning in maintenance of neuronal function ([@B4]), we propose that the Müller cell dysfunction observed in localized regions could play a role in the up-regulation of FTL expression within the inner retinal amacrine and ganglion cells. In support of this, Müller cells are known to directly modulate ganglion and amacrine cell function ([@B32]; [@B31]). In addition, these aberrant Müller cells within the FTL expressing regions may be sites of future glial scar/seal formation which is known to occur in phase 2/3 remodeling ([@B26]). Previous work has indicated that, at time periods equivalent to the initiation of FTL expression (\>P101), Müller cells exhibit distinct remodeling events, which contribute to the glial seal ([@B9]). Obviously further work will be required to determine whether these aberrant Müller cells modify the activity of their surrounding amacrine/ganglion cells, and serve as sites for future glial seals.

The Role of Cone Photoreceptors in FTL Up-Regulation
----------------------------------------------------

While the majority of cone photoreceptors are lost by P90 -- 100 in the rd1 mouse retina, cone remnants, including the presence of synaptic ribbons can remain for extended periods ([@B6]). Our data showed that areas exhibiting dysfunctional Müller cells corresponded to regions without cone photoreceptor terminals. These data could reflect the importance of residual cone terminals in glial cell function, with the ultimate loss of these terminals resulting in glial dysfunction and/or FTL up-regulation within the inner retina. This idea is supported by work showing that cone loss occurs in patches ([@B22]), similar to the pattern of observed glial changes in the current study. Furthermore, previous work has shown that the preservation of cones can preserve the inner neural retina from significantly remodeling ([@B26], [@B25]; [@B20]).

Significance of Findings for Photoreceptor Restorative Therapies
----------------------------------------------------------------

Many studies of the rd1 mouse retina have shown that there are structural and functional changes in inner retinal cells following photoreceptor loss ([@B42]; [@B44]; [@B25]; [@B27]; [@B38]). Bipolar and horizontal cells change morphology and retract their dendrites ([@B42]; [@B44]) as well as sprouting thin processes from their somata ([@B42]). Ganglion cells have shown changes in their oscillatory activity ([@B27]; [@B40]; [@B41]) and ion permeability ([@B25]; [@B8]). A caveat of many of these studies is that while they use animals at a stage when the majority of photoreceptors have died, they are in the early stages of the remodeling process (generally \<P100). Evidence from this study suggests that the FTL model may provide an early biomarker for glial scar formation and the loss of remnant cones at later stages in the retinal degeneration process, thus allowing these processes to be explored. In particular, it may be useful in identifying and targeting retinal regions that are more amenable to the implantation of vision restorative therapies.

In summary, the results of this study highlight that the rd1-FTL mouse may be a useful and unique tool for analysing retinal integrity during late stages of retinal degeneration. The strong up-regulation of *c-fos* reporter (FTL) that occurred well after photoreceptor loss and remained in the central retina throughout later stages of retinal degeneration, were independent of cell death, structural remodeling and any residual light response. Rather, it was associated with areas of dysfunctional glial cells and complete cone photoreceptor loss. Inhibiting these glial changes or preserving cone photoreceptors may assist with maintaining inner retinal integrity.
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